The Impact of Model Misspecification on the Individual Causal Association in Surrogate Endpoint Evaluation
- 12 July 2026
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 25 (4) , e70110
Abstract
Surrogate endpoints are often used in place of expensive, delayed, or rare clinical endpoints in clinical trials. However, regulatory authorities require thorough evaluation to accept these surrogate endpoints as reliable substitutes. One evaluation approach is the information‐theoretic causal inference framework, which quantifies surrogacy using the individual causal association (ICA). Like most causal inference methods, this approach relies on models that are only partially identifiable. For continuous outcomes, a normal model is often used. In this study, we explored the effects of model misspecification across various scenarios. We first considered true data‐generating mechanisms based on multivariate and log‐normal distributions. We then used D‐vine copulas with Gaussian, Clayton, Gumbel, and Frank families to vary the unidentifiable copulas involving counterfactual pairs while preserving the observable bivariate margins, and considered intuitive restrictions on nonidentified correlations, including positivity and conditional independence. In all settings, the identifiability issue was addressed through sensitivity analysis. Finally, we illustrate the proposed sensitivity analyses using clinical‐trial data from schizophrenia studies, evaluating the ICA under several modeling assumptions. The results show that, in most scenarios considered, the impact of model misspecification is small; however, certain departures from the assumed model can materially affect the surrogacy assessment.Keywords
Funding Information
- Agentschap Innoveren en Ondernemen
This publication has 26 references indexed in Scilit:
- A reflection on the causal interpretation of individual-level surrogacyJournal of Biopharmaceutical Statistics, 2019
- Robust estimation of the proportion of treatment effect explained by surrogate marker informationStatistics in Medicine, 2015
- Exploring the relationship between the causal‐inference and meta‐analytic paradigms for the evaluation of surrogate endpointsStatistics in Medicine, 2015
- On the Relationship between the Causal-Inference and Meta-Analytic Paradigms for the Validation of Surrogate EndpointsBiometrics, 2014
- Related Causal Frameworks for Surrogate OutcomesBiometrics, 2009
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments1998
- Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus HaloperidolThe British Journal of Psychiatry, 1995
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989